Dr Saar Gill is an associate professor of medicine in the division of hematology-oncology at the University of Pennsylvania. Since 2011 he has been working on developing genetically engineered immune cells for the treatment of cancer. Dr Gill is a physician-scientist who places a strong emphasis on translational research, and concepts developed in his laboratory have already led to several clinical trials for the treatment of hematologic malignancies. Dr. Gill co-founded Carisma Therapeutics, and recently co-founded Interius Biotherapeutics. He is a member of the American Society of Hematology Scientific Sub-Committee on Myeloid Neoplasia, elected to the American Society of Clinical Investigation, a past chair of the Cancer and Gene Therapy committee of the American Society of Gene & Cell Therapy.
Lab Website: https://www.med.upenn.edu/cci/gilllab